Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol)

This protocol examines an antibody–drug conjugate alongside radioimmunotherapy and cytokine support.

Technology in cancer research & treatment · Mar 13, 2026
Original authors: Meiling Xu, Yuehong Kong, Junjun Zhang, Rongzheng Chen, Pengfei Xing, Xiangrong Zhao, Shicheng Li, Yingying Xu, Liyuan Zhang, Li Zou

Study protocol: planned research, not a report of completed treatment outcomes.

Who was studied?

Planned enrollment: 62 patients with HER2-expressing advanced refractory solid tumors.

What does the publication report?

The primary planned endpoint is objective response rate, with survival, safety and quality-of-life assessments.

Safety findings

No completed trial toxicity rates are provided in this protocol.

How should we interpret it?

This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.